Search
Alnylam Pharmaceuticals Inc
ALNYAdd to Watchlist
206.380USD
-80.240-28.00%
Market hours （ET）Quotes delayed by 15 min
27.32BMarket Cap
50.51P/E TTM
More Details of Alnylam Pharmaceuticals Inc Company
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc Info
Ticker SymbolALNY
Company nameAlnylam Pharmaceuticals Inc
IPO dateMay 28, 2004
CEOGreenstreet (Yvonne L)
Number of employees2230
Security typeOrdinary Share
Fiscal year-endMay 28
Address675 W Kendall St
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142-1168
Phone16175518200
Websitehttps://www.alnylam.com/
Ticker SymbolALNY
IPO dateMay 28, 2004
CEOGreenstreet (Yvonne L)
Company Executives of Alnylam Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
FAQs
Who are the top five shareholders of Alnylam Pharmaceuticals Inc?
The top five shareholders of Alnylam Pharmaceuticals Inc are: Dr. Yvonne L. Greenstreet, M.D.
How many institutions hold shares of Alnylam Pharmaceuticals Inc (ALNY)?
As of 2026Q1, 1634 institutions hold shares of Alnylam Pharmaceuticals Inc, with a combined market value of approximately 133.66M, accounting for 100.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -6052832.00.
What is the biggest source of revenue for Alnylam Pharmaceuticals Inc?
In 2026Q1, the AMVUTTRA business generated the highest revenue for Alnylam Pharmaceuticals Inc, amounting to 2.31B and accounting for 62.30% of total revenue.